Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a retrospective multi-institutional study.

Published on Sep 29, 2021in Diabetes Research and Clinical Practice5.602
· DOI :10.1016/J.DIABRES.2021.109076
Fu-Chih Hsiao4
Estimated H-index: 4
(CGU: Chang Gung University),
Chia-Pin Lin5
Estimated H-index: 5
(CGU: Chang Gung University)
+ 2 AuthorsPao-Hsien Chu21
Estimated H-index: 21
(CGU: Chang Gung University)
Source
Abstract
Abstract null null Aims null To compare the risk of incident major adverse limb events (MALEs) between patients with type 2 diabetes (T2DM) who initiated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter-2 Inhibitors (SGLT2Is). null null null Methods null T2DM patients with prescriptions of GLP-1 RAs or SGLT2Is between January 1, 2016 and December 31, 2018 were retrospectively identified from a multi-institutional database. We used inverse probability of treatment weighting (IPTW) to balance covariates, and compared MALEs between GLP-1 RAs and SGLT2Is initiators using Fine and Gray subdistribution hazard model. null null null Results null There were 3,087 patients in the GLP-1 RAs group and 19,101 patients in the SGLT2Is group. After IPTW adjustment, the mean ages were 59.0 and 58.8 years, mean durations of diabetes were 6.4 years and 6.1 years, and 25.4% and 28.4% of the patients had cardiovascular disease, respectively. Lower extremity arterial disease was uncommon in both groups (2%). null Those who initiated GLP-1 RAs treatment were associated with reduced rate of MALEs (adjusted subdistribution hazard ratio [HR] 0.62, 95% confidence interval 0.46-0.83). null null null Conclusions null T2DM patients who received GLP-1 RAs treatment were associated with lower risk of MALEs compared to those who received SGLT2Is treatment.
References30
Newest
#1Insiya Poonawalla (Humana)H-Index: 1
#2Andy Bowe (Humana)H-Index: 2
Last. Phil Schwab (Humana)H-Index: 7
view all 5 authors...
AIMS To compare SGLT2 inhibitors and GLP-1 agonists on cardiovascular (CV) outcomes, treatment persistence/discontinuation, healthcare utilization and costs. METHODS This retrospective cohort study utilized medical and pharmacy claims to identify new SGLT2 inhibitor or GLP-1 agonist users from January 2015 to June 2017. A total of 5,507 patients were included in each treatment group after 1:1 propensity score matching. Cox proportional hazards models were used to compare CV outcomes and treatmen...
Source
#6Robert J. Glynn (Brigham and Women's Hospital)H-Index: 167
OBJECTIVE Both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally <65 years old and mostly with cardiovascular disease. We aimed to evaluate the comparative effectiveness and safety of SGLT2i and GLP-1RA among real-world older adults. RESEARCH DESIGN AND METHODS Using Medicare data (April 2013-December 2016), we identified 9...
Source
#1Suetonia C. Palmer (University of Otago)H-Index: 59
#2Britta Tendal (Monash University)H-Index: 8
Last. Giovanni F.M. Strippoli (University of Bari)H-Index: 81
view all 44 authors...
Abstract Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. Design Network meta-analysis. Data sources Medline, Embase, and Cochrane CENTRAL up to 11 August 2020. Eligibility criteria for selecting studies Randomised controlled trials comparing SGLT-2 inhibitors or GLP-1 receptor agonists with placebo, standard care, or other glucose lowering trea...
Source
#1Chen‐Yu Huang (NTU: National Taiwan University)H-Index: 1
#2Jen‐Kuang LeeH-Index: 1
OBJECTIVE Previous meta-analysis results showed that the use of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) is associated with an increased risk of lower extremity amputation. However, the effects of SGLT2i on specific lower extremity outcomes and whether outcome heterogeneity is based on key baseline characteristics remain unclear. METHODS We performed a quantitative meta-analysis of randomized, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes...
Source
#1Oriana Hoi Yun Yu (JGH: Jewish General Hospital)H-Index: 15
#2Sophie Dell'Aniello (JGH: Jewish General Hospital)H-Index: 27
Last. Lisa M. Lix (UM: University of Manitoba)H-Index: 67
view all 15 authors...
OBJECTIVE Reports of amputations associated with sodium–glucose cotransporter 2 (SGLT2) inhibitors have been inconsistent. We aimed to compare the risk of below-knee amputation with SGLT2 inhibitors versus dipeptidyl peptidase 4 (DPP-4) inhibitors among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This multicenter observational study used administrative health care databases from seven Canadian provinces and the U.K. Incident SGLT2 inhibitor users were matched to DPP-4 inhibitor us...
Source
#7Johannes F.E. Mann (UG: University of Groningen)H-Index: 66
#8John J. V. McMurray (UG: University of Groningen)H-Index: 1
Abstract Background Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or...
Source
#1Fabio Marsico (University of Naples Federico II)H-Index: 13
#2Stefania Paolillo (University of Naples Federico II)H-Index: 27
Last. Pasquale Perrone Filardi (University of Naples Federico II)H-Index: 27
view all 12 authors...
AIMS : Glucose-lowering, glucagon-like peptide-1 (GLP-1) receptor agonists reduce incidence of major cardiovascular (CV) events in patients with Type 2 diabetes mellitus (DM). However, randomized clinical trials reported inconsistent effects on myocardial infarction (MI) and stroke, and limited data in DM patients without established CV disease (CVD). Very recently, new relevant evidence was available from additional CV outcome trials (CVOTs) that also included large subgroups of patients with D...
Source
#1Hertzel C. Gerstein (HHS: Hamilton Health Sciences)H-Index: 115
#2Robert G. Hart (Population Health Research Institute)H-Index: 103
view all 29 authors...
Summary Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c w...
Source
#1Søren Lund Kristensen (Glas.: University of Glasgow)H-Index: 28
#2Rasmus Rørth (Glas.: University of Glasgow)H-Index: 14
Last. John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
view all 9 authors...
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. Methods We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled...
Source
#1Rewind Investigators (Population Health Research Institute)H-Index: 2
#2Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 83
Last. Rewind InvestigatorsH-Index: 1
view all 1 authors...
Summary Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries. Men and women aged at leas...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.